AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01670071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release
Description: Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
Study NCT01670071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone immediate-release
Description: Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
Study NCT03796000 — intervention group
Intervention type: PROCEDURE
Intervention: tissue samples, blood and stool sample
Description: Tissue samples from gastroscopy/colonoscopy.
Study NCT01059019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Omega-3 Fatty Acid Supplements
Description: Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
Study NCT01059019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid Supplements
Description: Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
Study NCT04202536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir Dipivoxil Maleate
Description: Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
Study NCT04202536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate(TDF)
Description: 300 mg tablet administered orally once daily Other Name: VIREAD®
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin plus metformin
Description: Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to metformin
Description: Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to sitagliptin plus metformin
Description: Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin plus metformin XR
Description: Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to metformin XR
Description: Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the Sitagliptin/Metformin and Metformin arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the Sitagliptin/Metformin XR and Metformin XR arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine.
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the Sitagliptin/Metformin and Metformin arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the Sitagliptin/Metformin XR and Metformin XR arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine.
Study NCT01263054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransDiscal System
Description: Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
Study NCT01263054 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical Management
Description: Standard medical management, physical therapy, and lifestyle changes.
Study NCT01158989 — intervention group
Intervention type: DEVICE
Intervention: PillCam
Description: Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to sitagliptin plus metformin XR
Description: Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.
Study NCT01760447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin XR
Description: Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
Study NCT04350931 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intradermal injection of BCG Vaccine
Description: 0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds
Study NCT01390350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 150mg subcutaneous injections on day 0
Study NCT01390350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg subcutaneous injections on day 0
Study NCT04618380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
Description: The following clinical indexes are evaluated:~1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test.
Study NCT00003495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT03188653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CeraVe® Eczema Soothing Body Wash
Description: One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash
Study NCT03188653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil® RestoraDerm® Eczema Calming Body Wash
Description: One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash
Study NCT03188653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dove® Sensitive Skin Body Wash
Description: One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash
Study NCT03188653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eucerin® Skin Calming Body Wash
Description: One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash
Study NCT03188653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aveeno® Skin Relief Body Wash
Description: One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash
Study NCT03188653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MooGoo® Milk Wash
Description: One of the 7 arm locations will be selected to receive MooGoo® Milk Wash
Study NCT03188653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free & Clear Liquid Cleanser
Description: One of the 7 arm locations will be selected to receive Free \& Clear Liquid Cleanser
Study NCT00513786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
Study NCT00513786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
Study NCT00513786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
Study NCT04833478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety
Description: Techniques used to reduce anxiety in paediatric patients.
Study NCT02132871 — intervention group
Intervention type: DEVICE
Intervention: Impedance cardiography Physioflow ®
Study NCT02270307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose 50 mg/kg at day +3,+4 once daily
Study NCT02270307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Dose 1 million per kg, at day of recovery once
Study NCT02706249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Study NCT04147195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS006
Description: 5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks
Study NCT04147195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor
Description: 100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks
Study NCT00739115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliox gas
Description: Heliox gas used in conjunction with nasal CPAP
Study NCT02474849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
Study NCT02474849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
Study NCT00930956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: 30 g of carbohydrate per Arm
Study NCT00930956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch
Description: 30 g of carbohydrate per Arm
Study NCT04350931 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus
Study NCT04627558 — intervention group
Intervention type: OTHER
Intervention: stroke patients, balance assessment
Description: validity relability dubousset functional test
Study NCT04295369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep, stress management, and Chinese dietary recommendations.
Study NCT01335906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
Study NCT04794673 — intervention group
Intervention type: OTHER
Intervention: brain damage
Description: Have or not have the brain damage and the location of the damage
Study NCT01718951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: golimumab
Description: golimumab
Study NCT02932605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02932605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol
Study NCT02004314 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chloroquine
Study NCT01711008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cereal
Study NCT01711008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No breakfast
Study NCT04406116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave coagulation using HS1 Instrument
Description: Microwave therapy at 5.8 GHz
Study NCT02462109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.
Study NCT02799888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.
Study NCT02799888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (in HLA-Unrelated Donor Transplantation)
Description: Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.
Study NCT02799888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (in HLA-Mismatched Related Donor Transplantation)
Description: Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
Study NCT02799888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered intravenously at a dose of 15 mg/m\^2 on day +1, and 10 mg/m\^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10\^9/L.
Study NCT04728984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalfurafine Hydrochloride
Description: Nalfurafine Hydrochloride 2.5μg\*2~; Oral administration after dinner, once daily for 14 consecutive days
Study NCT04728984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalfurafine Hydrochloride+Placebo
Description: Nalfurafine Hydrochloride 2.5μg+ A placebo pill; Oral administration after dinner, once daily for 14 consecutive days
Study NCT04728984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two placebo pills; Oral administration after dinner, once daily for 14 consecutive days
Study NCT03571724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Menthol Very Low Nicotine Cigarettes
Description: King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco
Study NCT03571724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Very Low Nicotine Cigarettes
Description: King size menthol cigarettes containing 0.4mg nicotine /g tobacco
Study NCT03571724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject's UB non-mentholated filtered cigarettes
Description: King size non-menthol cigarettes
Study NCT03571724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject's UB mentholated filtered cigarettes
Description: King size menthol cigarettes
Study NCT01718951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Description: pamidronate
Study NCT01699737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-851
Study NCT01699737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Encapsulated Glimepiride tablets
Study NCT01699737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Active
Study NCT01699737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Active
Study NCT01699737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for comparator
Study NCT01699737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for comparator
Study NCT01921361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: Intrathecal 3ml (15 mg)
Study NCT01921361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Intrathecal 3ml (15 mg)
Study NCT01921361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intrathecal 3 microgram (diluted 1/10, 0.3 ml)
Study NCT01921361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion (dexmedetomidine diluted 1 microgram/ml)
Study NCT01921361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.
Study NCT01921361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.
Study NCT03065933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release clonidine
Description: Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
Study NCT03533777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral intravenous catheter placement
Description: The region of the upper extremity in which the IV will be placed will be prepped with chlorhexidine and a proximal elastic tourniquet is applied to the upper arm. A 20 gauge 30 millimeter IV catheter is inserted into an upper extremity vein by an anesthesiologist in either an antegrade or retrograde direction depending on which treatment arm the study subject is randomized to.